Please login to the form below

Not currently logged in
Email:
Password:

sapropterin dihydrochloride

This page shows the latest sapropterin dihydrochloride news and features for those working in and with pharma, biotech and healthcare.

FDA pauses BioMarin gene therapy trial

FDA pauses BioMarin gene therapy trial

It’s products include Vimizim (elosulfase alfa) for MPS type IVA (Morquio A syndrome), Naglazyme (galsulfase) for MPS VI (Maroteaux-Lamy syndrome) and Kuvan (sapropterin dihydrochloride) in children with PKU.

Latest news

  • Judge forces NHS England rethink on Kuvan Judge forces NHS England rethink on Kuvan

    BioMarin won EU approval in 2008 for Kuvan (sapropterin dihydrochloride), a drug that is used alongside a phenylalanine-restricted diet to reduce levels of amino acid even further, but so far

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2015 Deal Watch October 2015

    In the original PKU-focused deal dating back to 2005, Merck signed an exclusive licence with BioMarin for the oral drug Kuvan (sapropterin dihydrochloride), which is now marketed, and an option

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....